Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS4134-TPS4134 ◽  
Author(s):  
Markus H. Moehler ◽  
Julien Taïeb ◽  
Jayne S. Gurtler ◽  
Huiling Xiong ◽  
Jenny Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Maintenance Therapy ◽  
Locally Advanced ◽  
Metastatic Gastric Cancer ◽  
First Line ◽  
Phase 3 ◽  
Line Chemotherapy

Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer

2015 ◽  
Vol 15 (5) ◽  
pp. 595-601 ◽  
Author(s):  
Chunmei Shi ◽  
Qiang Chen ◽  
Songfei Shen ◽  
Riping Wu ◽  
Baoyu Yang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Locally Advanced ◽  
Metastatic Gastric Cancer ◽  
First Line ◽  
Line Chemotherapy

Oxaliplatin, 5-fluorouracil, and folinic acid as first-line chemotherapy for elderly patients with advanced gastric cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14155-14155 ◽  
Author(s):  
I. Choi ◽  
K. Lee ◽  
D. Oh ◽  
J. Kim ◽  
S. Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Elderly Patients ◽  
Folinic Acid ◽  
Advanced Gastric Cancer ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Complete Response ◽  
Metastatic Gastric Cancer ◽  
First Line ◽  
Line Chemotherapy

14155 Background: We investigated the efficacy and safety of an oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line chemotherapy for elderly patients with advanced gastric cancer. Methods: Chemotherapy-naïve patients (≥65 yr of age) with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour intravenous infusion), then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 14 days. Results: A total of 24 patients were enrolled between September 2003 and July 2005. Of 22 evaluable patients, none achieved complete response (CR) and 11 achieved partial response (PR), resulting in an overall response rate of 50%. Median progression-free survival (PFS) was 5.4 months (95% CI: 5.1–5.8 months) and median overall survival (OS) was 7.4 months (95% CI: 4.4–10.4 months). The main toxicities were anemia and leucopenia, which were observed in 39.8% and 19.0%, respectively, of the total cycles administered. There were 2 cycles of grade 4 leucopenia and febrile neutropenia was not observed. Conclusions: This oxaliplatin/5-FU/FA regimen shows good efficacy and an acceptable toxicity profile in elderly patients with advanced gastric cancer. No significant financial relationships to disclose.

scholarly journals A prognostic model using inflammatory response markers in metastatic gastric cancer (GC) pts before first-line chemotherapy

2016 ◽  
Vol 27 ◽  
pp. iv20
Author(s):  
A. Petrillo ◽  
M.M. Laterza ◽  
J. Ventriglia ◽  
B. Savastano ◽  
G. Tirino ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Inflammatory Response ◽  
Prognostic Model ◽  
Metastatic Gastric Cancer ◽  
First Line ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document